2 0 OCT 2003

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
A61K 45/00, 9/20, A61P 3/06

A1

(11) International Publication Number: WO 00/62810

(43) International Publication Date: 26 October 2000 (26.10.00)

(21) International Application Number: PCT/SE00/00755

(22) International Filing Date: 19 April 2000 (19.04.00)

(30) Priority Data:
9901387-2 19 April 1999 (19.04.99) SE

(71) Applicant *(for all designated States except US)*: ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: ABRAHAMSSON, Bertil [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). LINDQVIST, Ann-Margret [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). UNGELL, Anna-Lena [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE).

(74) Agent: ASTRAZENECA AB; Global Intellectual Property, Patents, S-151 85 Södertälje (SE).

(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: AN ORAL FORMULATION FOR ILEUM ADMINISTERING COMPRISING AN INHIBITOR COMPOUND OF THE ILEAL BILE ACID TRANSPORT

(57) Abstract

An oral pharmaceutical formulation comprising an inhibitor compound of the ileal bile acid transport (IBAT inhibitor compound) and a therapeutically acceptable carrier characterised in that the formulation is designed to deliver the IBAT inhibitor compound in the ileum. The IBAT inhibitor compound can also be administered in combination with a bile acid binder to alleviate possible side effects of therapy with IBAT inhibitor compound, such as for instance diarrhoea. The bile acid binder may be formulated for colon release.



162162



G00001